AU2003210153A1 - Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound - Google Patents

Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound

Info

Publication number
AU2003210153A1
AU2003210153A1 AU2003210153A AU2003210153A AU2003210153A1 AU 2003210153 A1 AU2003210153 A1 AU 2003210153A1 AU 2003210153 A AU2003210153 A AU 2003210153A AU 2003210153 A AU2003210153 A AU 2003210153A AU 2003210153 A1 AU2003210153 A1 AU 2003210153A1
Authority
AU
Australia
Prior art keywords
administering
ige antibody
allergic disease
combination treatments
antiallergic compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003210153A
Other languages
English (en)
Inventor
Howard George Fox
Charles Edward Owen
Christoph Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2003210153A1 publication Critical patent/AU2003210153A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2003210153A 2002-01-09 2003-01-09 Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound Abandoned AU2003210153A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0200429.9A GB0200429D0 (en) 2002-01-09 2002-01-09 Organic compounds
GB0200429.9 2002-01-09
PCT/EP2003/000154 WO2003057249A1 (en) 2002-01-09 2003-01-09 Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound

Publications (1)

Publication Number Publication Date
AU2003210153A1 true AU2003210153A1 (en) 2003-07-24

Family

ID=9928810

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003210153A Abandoned AU2003210153A1 (en) 2002-01-09 2003-01-09 Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound

Country Status (9)

Country Link
US (2) US20050042215A1 (https=)
EP (1) EP1465662A1 (https=)
JP (1) JP2005514414A (https=)
CN (1) CN1612751A (https=)
AU (1) AU2003210153A1 (https=)
BR (1) BR0306732A (https=)
CA (1) CA2472151A1 (https=)
GB (1) GB0200429D0 (https=)
WO (1) WO2003057249A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005512946A (ja) * 2001-05-09 2005-05-12 ノバルティス アクチエンゲゼルシャフト 選択的免疫調節法
GB0307867D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
CA2539324A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
WO2005030331A1 (en) * 2003-09-26 2005-04-07 Fairfield Clinical Trials, Llc Combination antihistamine medication
GB0502358D0 (en) * 2005-02-04 2005-03-16 Novartis Ag Organic compounds
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
JP4974903B2 (ja) * 2005-02-09 2012-07-11 参天製薬株式会社 疾患または状態を処置するための液体処方物
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
PL2001466T3 (pl) 2006-03-23 2016-06-30 Santen Pharmaceutical Co Ltd Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
AU2008215926B2 (en) * 2007-02-15 2012-07-19 Astrazeneca Ab Binding members for IgE molecules
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
BR112020006339A2 (pt) * 2017-11-07 2020-11-03 Hubit Genomix, Inc. método para prevenção primária de distúrbios alérgicos durante a infância através de imunossupressão específica da classe ige
US20210115155A1 (en) * 2018-03-26 2021-04-22 Novartis Ag Methods of treating chronic spontaneous urticaria using ligelizumab
CN114504644B (zh) * 2021-12-24 2024-02-13 北京大学第一医院 抗IgE抗体在用于治疗腺样体肥大中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
WO2000016804A1 (en) * 1998-09-18 2000-03-30 Dynavax Technologies Corporation METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN
GB0012383D0 (en) * 2000-05-22 2000-07-12 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CA2472151A1 (en) 2003-07-17
CN1612751A (zh) 2005-05-04
US20050042215A1 (en) 2005-02-24
JP2005514414A (ja) 2005-05-19
WO2003057249A1 (en) 2003-07-17
BR0306732A (pt) 2004-12-28
GB0200429D0 (en) 2002-02-27
EP1465662A1 (en) 2004-10-13
US20060240000A1 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
AU2003210153A1 (en) Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound
AU2003246102A1 (en) Method of examining allergic disease and drug for treating the same
AU2003243551A1 (en) Use of an anti-endotoxin drug in the prevention and treatment of disease
AU2003216585A1 (en) Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases
AU2003290548A1 (en) Prevention and treatment of synucleinopathic disease
AU2003268531A1 (en) Materials and methods for treatment of allergic diseases
AU2003295773A1 (en) Treatment of liver disease with active vitamin d compounds
AU2002346504A1 (en) Therapeutic protein and treatments
AU2003299581A1 (en) Antibodies against drugs of abuse
AU2003304410A1 (en) Agents and methods for treatment of disease by oligosaccharide targeting agents
AU2002950853A0 (en) Aminopyrimidine compound and pharmaceutical use thereof
AU2003227148A1 (en) Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
AU2003243663A1 (en) Vaccines for suppressing ige-mediated allergic disease and methods for using the same
AU2003225944A1 (en) Modified release dosage forms with two cores and an opening
AU2003238242A1 (en) Use of an anti-endotoxin drug in the prevention and treatment of disease
AU2003283727A1 (en) Recording start and stop
AU2003255544A1 (en) Tumor specific oligosaccharide epitopes and use thereof
AU2003244132A1 (en) Method of examining allergic disaese and drug for treating the same
HK1069989A (en) Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound
AU2003290663A1 (en) Assay for tissue factor and factor viia
AU2003284597A1 (en) Apoptosis-associated protein and use thereof
AU2003265281A1 (en) Methods and compositions for the enhancement of wound healing
AU2003240052A1 (en) Il-11 derivatives and therapeutic uses thereof
AU2003227361A1 (en) DECOY FOR TREATING AND/OR PREVENTING Th2 CYTOKINE-ASSOCIATED ALLERGIC DISEASE, GATA3 MUTANT PROTEIN AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
AUPS295802A0 (en) Metallothionein based neuronal therapeutic and therapeutic methods

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase